Skip to main content
Drimble Massachusetts

Biogen CEO: 'Major bottleneck' still limits Alzheimer's drug

A new Alzheimers drug from Biogen brought in only $300,000 in sales during its first full quarter on the market, continuing a slow debut complicated by...

Topics

More from Massachusetts Non-Local Sources